Evaluation of drugs for the treatment of gastroesophageal reflux disease (GORD) - Scientific guideline
HumanScientific guidelines
This document addresses the European regulatory position on the development of products for the treatment of gastro-oesophageal reflux disease in adults and children.
Keywords: Gastro-oesophageal reflux disease (GORD), reflux oesophagitis, non-erosive reflux disease (NERD)
Current effective version
Guideline on the evaluation of drugs for the treatment of gastro-oesophageal reflux disease
Consultation dates:
to AdoptedLegal effective date: Reference Number: EMA/CHMP/EWP/342691/2009
English (EN) (264.43 KB - PDF)
First published: Last updated:
Document history
Guideline on the evaluation of drugs for the treatment of gastro-oesophageal reflux disease
Consultation dates:
to AdoptedLegal effective date: Reference Number: EMA/CHMP/EWP/342691/2009
English (EN) (264.43 KB - PDF)
First published: Last updated:
Overview of comments received on 'guideline on the evaluation of drugs for the treatment of gastro-oesophageal reflux disease'
Reference Number: EMA/131448/2011
English (EN) (284.02 KB - PDF)
First published: Last updated:
Draft guideline on the evaluation of drugs for the treatment of gastroesophageal reflux disease
Consultation dates:
to Draft: consultation closedReference Number: EMEA/CHMP/EWP/342691/2009
English (EN) (133.38 KB - PDF)
First published: Last updated:
Concept paper on the need for a guideline on the evaluation of drugs for the treatment of Gastroesophageal Reflux disease (GERD)
Consultation dates:
to Reference Number: EMEA/CHMP/EWP/15839/2009
English (EN) (63.21 KB - PDF)
First published: Last updated:
Related content
- Clinical efficacy and safety: alimentary tract and metabolism
- Directive 2001/83/EC
- Choice of a non-inferiority margin
- Conduct of pharmacovigilance for medicines used by the paediatric population
- Extrapolation of results from clinical studies conducted outside Europe to the EU-population
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E6 (R1) Good clinical practice
- ICH E8 General considerations for clinical trials
- ICH E9 Statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- Investigation of drug interactions
- Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products